Social Determinants of Health and Market Access

04/01/24 • 25 min

Many pharmaceutical companies say attacking health inequities is a strategic objective, but addressing the topic is hard to do. Why is this so?

This episode's guest, Elisa Remoundos, Senior Vice President and Group Creative Director for Entrée Health, believes that for pharma and market access to tackle health inequities they need to rethink the social determinants of health that can have a huge impact on adherence, compliance, health outcomes, and societal burdens.

Elisa also wrote about SDoH and market acccess here.

Follow Elisa on LinkedIn.

Follow Valuate on LinkedIn or learn more here.

Many pharmaceutical companies say attacking health inequities is a strategic objective, but addressing the topic is hard to do. Why is this so?

Elisa also wrote about SDoH and market acccess here.

Follow Elisa on LinkedIn.

Follow Valuate on LinkedIn or learn more here.

Previous Episode

A Payer’s Perspective on Prior Authorization

What do payers think about prior authorization?

Dr. Andrew Hertler is Chief Medical Officer at Evolent Health. He recently co-authored an op-ed about prior authorization, touching on gold-carding, a controversial solution to addressing prior authorization challenges.

Joining Hertler is regular guest John Hennessy, a Principal with Valuate.

Topics include:

Why exceptions can sometimes be problematic.
What happens after a prior authorization is rejected.
Pathways: Who makes the decisions? How are they updated?
How should pharma think about payers?
What can manufacturers and market access do to help pathways?

Follow Andrew on LinkedIn.

Follow Valuate on LinkedIn

Learn more about Valuate.

Next Episode

Message Testing and Market Access

What message is your prescription drug delivering?

Before manufacturers debut a new prescription drug they need to create a strategy to optimize coverage and commercialization. But part of that strategy consists of crafting a message that resonates with patients, providers and payers. And that’s where a lot of manufacturers get tripped up.

Alex Mindlin of Valuate Health joins The IDI to explain how she validates manufacturers’ value messaging by combining strategic content and market research -- what she calls “creative market research.”

Follow Alex on LinkedIn.

Follow Valuate Health on LinkedIn or on the web.